These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 29055841)

  • 1. Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: A meta-regression of randomised prospective studies.
    Roviello G; Andre F; Venturini S; Pistilli B; Curigliano G; Cristofanilli M; Rosellini P; Generali D
    Eur J Cancer; 2017 Nov; 86():257-265. PubMed ID: 29055841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: a meta-regression of 29 randomized prospective studies.
    Berruti A; Amoroso V; Gallo F; Bertaglia V; Simoncini E; Pedersini R; Ferrari L; Bottini A; Bruzzi P; Sormani MP
    J Clin Oncol; 2014 Dec; 32(34):3883-91. PubMed ID: 25349292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers: A Systematic Review and Meta-analysis.
    Ritchie G; Gasper H; Man J; Lord S; Marschner I; Friedlander M; Lee CK
    JAMA Oncol; 2018 Apr; 4(4):522-528. PubMed ID: 29470579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis.
    Conforti F; Pala L; Bagnardi V; De Pas T; Martinetti M; Viale G; Gelber RD; Goldhirsch A
    Lancet Oncol; 2018 Jun; 19(6):737-746. PubMed ID: 29778737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Overall Response Rate and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Immunotherapy Trials.
    Mushti SL; Mulkey F; Sridhara R
    Clin Cancer Res; 2018 May; 24(10):2268-2275. PubMed ID: 29326281
    [No Abstract]   [Full Text] [Related]  

  • 6. The impact of high PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1/PD-L1 antibodies in non-small cell lung cancer.
    Ito K; Miura S; Sakaguchi T; Murotani K; Horita N; Akamatsu H; Uemura K; Morita S; Yamamoto N
    Lung Cancer; 2019 Feb; 128():113-119. PubMed ID: 30642442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysis.
    Kaufman HL; Schwartz LH; William WN; Sznol M; Fahrbach K; Xu Y; Masson E; Vergara-Silva A
    J Cancer Res Clin Oncol; 2018 Nov; 144(11):2245-2261. PubMed ID: 30132118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between sex and efficacy of immune checkpoint inhibitors (PD-1 and CTLA-4 inhibitors).
    Wu Y; Ju Q; Jia K; Yu J; Shi H; Wu H; Jiang M
    Int J Cancer; 2018 Jul; 143(1):45-51. PubMed ID: 29424425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Older and younger patients treated with immune checkpoint inhibitors have similar outcomes in real-life setting.
    Corbaux P; Maillet D; Boespflug A; Locatelli-Sanchez M; Perier-Muzet M; Duruisseaux M; Kiakouama-Maleka L; Dalle S; Falandry C; Péron J
    Eur J Cancer; 2019 Nov; 121():192-201. PubMed ID: 31590080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune-checkpoint inhibitors and candidate surrogate endpoints for overall survival across tumour types: A systematic literature review.
    Branchoux S; Bellera C; Italiano A; Rustand D; Gaudin AF; Rondeau V
    Crit Rev Oncol Hematol; 2019 May; 137():35-42. PubMed ID: 31014514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship Between Progression-Free Survival, Objective Response Rate, and Overall Survival in Clinical Trials of PD-1/PD-L1 Immune Checkpoint Blockade: A Meta-Analysis.
    Ye J; Ji X; Dennis PA; Abdullah H; Mukhopadhyay P
    Clin Pharmacol Ther; 2020 Dec; 108(6):1274-1288. PubMed ID: 32564368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of objective response, disease control and progression-free survival as surrogate end-points for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials.
    Nie RC; Chen FP; Yuan SQ; Luo YS; Chen S; Chen YM; Chen XJ; Chen YB; Li YF; Zhou ZW
    Eur J Cancer; 2019 Jan; 106():1-11. PubMed ID: 30453169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of Milestone Restricted Mean Survival Time Ratio With Overall Survival Hazard Ratio in Randomized Clinical Trials of Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
    Wang ZX; Wu HX; Xie L; Wang YN; Yang LP; He MM; Luo HY; Ding PR; Xie D; Chen G; Li YH; Wang F; Xu RH
    JAMA Netw Open; 2019 May; 2(5):e193433. PubMed ID: 31050784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Comparison of Response Patterns for Progression-Free Survival and Overall Survival Following Treatment for Cancer With PD-1 Inhibitors: A Meta-analysis of Correlation and Differences in Effect Sizes.
    Gyawali B; Hey SP; Kesselheim AS
    JAMA Netw Open; 2018 Jun; 1(2):e180416. PubMed ID: 30646078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between immune-related adverse events and long-term survival outcomes in patients treated with immune checkpoint inhibitors.
    Maillet D; Corbaux P; Stelmes JJ; Dalle S; Locatelli-Sanchez M; Perier-Muzet M; Duruisseaux M; Kiakouama-Maleka L; Freyer G; Boespflug A; Péron J
    Eur J Cancer; 2020 Jun; 132():61-70. PubMed ID: 32334337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progression-free survival is simply a measure of a drug's effect while administered and is not a surrogate for overall survival.
    Wilkerson J; Fojo T
    Cancer J; 2009; 15(5):379-85. PubMed ID: 19826357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy.
    Tang PA; Bentzen SM; Chen EX; Siu LL
    J Clin Oncol; 2007 Oct; 25(29):4562-8. PubMed ID: 17876010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials.
    Wang ZX; Wu HX; Xie L; Lin WH; Liang F; Li J; Yang ZM; Xu RH
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer.
    Foster NR; Renfro LA; Schild SE; Redman MW; Wang XF; Dahlberg SE; Ding K; Bradbury PA; Ramalingam SS; Gandara DR; Shibata T; Saijo N; Vokes EE; Adjei AA; Mandrekar SJ
    J Thorac Oncol; 2015 Jul; 10(7):1099-106. PubMed ID: 26134227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Individual- and trial-level surrogacy in colorectal cancer.
    Buyse M; Burzykowski T; Michiels S; Carroll K
    Stat Methods Med Res; 2008 Oct; 17(5):467-75. PubMed ID: 18285439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.